Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
137 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Autism - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Autism - Pipeline Review, H1 2016', provides an overview of the Autism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Autism and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Autism - The report reviews pipeline therapeutics for Autism by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Autism therapeutics and enlists all their major and minor projects - The report assesses Autism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Autism Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Autism - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Autism Overview 10 Therapeutics Development 11 Pipeline Products for Autism - Overview 11 Pipeline Products for Autism - Comparative Analysis 12 Autism - Therapeutics under Development by Companies 13 Autism - Therapeutics under Investigation by Universities/Institutes 15 Autism - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Autism - Products under Development by Companies 20 Autism - Products under Investigation by Universities/Institutes 22 Autism - Companies Involved in Therapeutics Development 23 Addex Therapeutics Ltd 23 Aequus Pharmaceuticals Inc. 24 AgeneBio Inc. 25 APeT Holding BV 26 Berg LLC 27 BioCrea GmbH 28 BrainStorm Cell Therapeutics Inc. 29 Cellceutix Corporation 30 Confluence Pharmaceuticals LLC 31 Curemark, LLC 32 Domain Therapeutics SA 33 F. Hoffmann-La Roche Ltd. 34 Heptares Therapeutics Limited 35 Intra-Cellular Therapies, Inc. 36 Luc Therapeutics, Inc. 37 MedDay 38 Omeros Corporation 39 Otsuka Holdings Co., Ltd. 40 Retrophin Inc. 41 Sage Therapeutics, Inc. 42 Saniona AB 43 Sumitomo Dainippon Pharma Co., Ltd. 44 Autism - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Combination Products 46 Assessment by Target 47 Assessment by Mechanism of Action 49 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 (dextromethorphan + quinidine sulfate) - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 ADX-71441 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 ADX-88178 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 aripiprazole - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 aripiprazole - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 carbetocin - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 CM-AT - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Drug for Autism - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 histamine dihydrochloride - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 HTL-14242 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ITI-007 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 KM-391 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 lurasidone hydrochloride - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 MD-1103 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 niacinamide CR - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 oxytocin - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 RG-7314 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 SF-999 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 SGE-872 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecule to Agonise GABRA5 Receptor for CNS Disorders - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecule to Target GPR63 for Autism - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Small Molecules to Agonize Metabotropic Glutamate Receptor 4 for Autism - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 SNA-1 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism and Bronchopulmonary Dysplasia - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Autism - Recent Pipeline Updates 96 Autism - Dormant Projects 128 Autism - Discontinued Products 130 Autism - Product Development Milestones 131 Featured News & Press Releases 131 Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch 131 Dec 07, 2015: Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism 131 Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole 132 May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism 132 Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment 133 Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt 133 Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 133 Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 134 Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism 134 Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors 134 Appendix 136 Methodology 136 Coverage 136 Secondary Research 136 Primary Research 136 Expert Panel Validation 136 Contact Us 136 Disclaimer 137
List of Tables Number of Products under Development for Autism, H1 2016 11 Number of Products under Development for Autism - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Comparative Analysis by Unknown Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2016 22 Autism - Pipeline by Addex Therapeutics Ltd, H1 2016 23 Autism - Pipeline by Aequus Pharmaceuticals Inc., H1 2016 24 Autism - Pipeline by AgeneBio Inc., H1 2016 25 Autism - Pipeline by APeT Holding BV, H1 2016 26 Autism - Pipeline by Berg LLC, H1 2016 27 Autism - Pipeline by BioCrea GmbH, H1 2016 28 Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2016 29 Autism - Pipeline by Cellceutix Corporation, H1 2016 30 Autism - Pipeline by Confluence Pharmaceuticals LLC, H1 2016 31 Autism - Pipeline by Curemark, LLC, H1 2016 32 Autism - Pipeline by Domain Therapeutics SA, H1 2016 33 Autism - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 34 Autism - Pipeline by Heptares Therapeutics Limited, H1 2016 35 Autism - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 36 Autism - Pipeline by Luc Therapeutics, Inc., H1 2016 37 Autism - Pipeline by MedDay, H1 2016 38 Autism - Pipeline by Omeros Corporation, H1 2016 39 Autism - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 40 Autism - Pipeline by Retrophin Inc., H1 2016 41 Autism - Pipeline by Sage Therapeutics, Inc., H1 2016 42 Autism - Pipeline by Saniona AB, H1 2016 43 Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 44 Assessment by Monotherapy Products, H1 2016 45 Assessment by Combination Products, H1 2016 46 Number of Products by Stage and Target, H1 2016 48 Number of Products by Stage and Mechanism of Action, H1 2016 50 Number of Products by Stage and Route of Administration, H1 2016 53 Number of Products by Stage and Molecule Type, H1 2016 55 Autism Therapeutics - Recent Pipeline Updates, H1 2016 96 Autism - Dormant Projects, H1 2016 128 Autism - Dormant Projects (Contd..1), H1 2016 129 Autism - Discontinued Products, H1 2016 130
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
